AgomAb Therapeutics NV Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, AgomAb Therapeutics NV stock has a consensus rating of "Buy" and an average price target of $32. The average 1-year stock price forecast is 223.89% higher than the current stock price, while the lowest is $28 (+183.40%) and the highest is $36 (+264.37%).

Price Target: $32 (+223.89%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$28	$32	$32	$36
Change	+183.40%	+223.89%	+223.89%	+264.37%

Analyst Ratings

The average analyst rating for AgomAb Therapeutics NV stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '26	Apr '26	May '26
Strong Buy	1	1	1
Buy	2	2	2
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Maintains $28 → $11	Buy	Maintains	$28 → $11	+6.78%	May 18, 2026
Anupam Rama J.P. Morgan	J.P. Morgan	Buy Initiates $32	Buy	Initiates	$32	+223.89%	Mar 3, 2026
Thomas Smith Leerink Partners	Leerink Partners	Buy Initiates $36	Buy	Initiates	$36	+264.37%	Mar 3, 2026

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.83

from -167.76

EPS Next Year

-2.00

from -1.83

Fiscal Year	FY 2019	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2019	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-3.09M	-22.63M	-31.19M	-48.02M	-59.28M	-79.21M
Net Income	-3.05M	-8.14M	-11.39M	-46.27M	-62.55M	-70.19M
EPS	-	-	-	-	-167.76	-1.83
Free Cash Flow	-	-	-49.90M	-16.51M	-24.37M	-17.00M
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.83
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-